Compare ADTN & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | OCGN |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.8M | 474.8M |
| IPO Year | 1996 | 2014 |
| Metric | ADTN | OCGN |
|---|---|---|
| Price | $6.42 | $0.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $14.67 | $12.17 |
| AVG Volume (30 Days) | 1.4M | ★ 5.9M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,083,807,000.00 | N/A |
| Revenue This Year | $5.74 | $12.33 |
| Revenue Next Year | $7.88 | $10.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.46 | N/A |
| 52 Week Low | $6.29 | $0.78 |
| 52 Week High | $19.98 | $2.73 |
| Indicator | ADTN | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 25.38 |
| Support Level | $6.29 | N/A |
| Resistance Level | $7.34 | $1.12 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 8.62 | 0.77 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").